Matches in SemOpenAlex for { <https://semopenalex.org/work/W2340873090> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W2340873090 endingPage "396" @default.
- W2340873090 startingPage "381" @default.
- W2340873090 abstract "The staging, screening and diagnosis, and treatment of prostate cancer are discussed. Prostate cancer kills about 40,000 men in the United States each year. Signs and symptoms range from dysuria to features of advanced metastatic disease. The American Urological System of staging prostate cancer designates four stages, A through D. The tumor is graded histologically with the Gleason scale. Methods used in the screening and diagnosis of prostate cancer include digital rectal examination, the prostate-specific antigen (PSA) assay, biopsy, transrectal ultrasonography, and determination of PSA density, velocity, and age specificity. The value of screening and treatment remains controversial because tumors are generally slow-growing and conclusive data showing an effect on survival time are lacking. Treatment methods consist of prostatectomy, radiation therapy, and hormonal drug therapy or bilateral orchiectomy. The choice is influenced primarily by the stage of the disease but also by the patient’s age, physical condition, and response to prior therapy. Patients with stage A or B disease are considered for prostatectomy or radiation therapy. The primary treatment for stage C disease is radiation therapy. For stage D, the main approaches are watchful waiting and bilateral orchiectomy or hormonal drug therapy to reduce androgenic stimulation of prostate tissue. Long-term survival rates are high for stages A and B and considerably lower for stages C and D. Prostate cancer responds to estrogens, but adverse effects are frequent and potentially severe. Luteinizing hormone-releasing hormone agonists (leuprolide and goserelin) are as effective as estrogens but have less toxicity; a disadvantage of these agents is an initial flaring of the disease. Other hormonal agents used include antiandrogens-progestins, flutamide, and bicalutamide. Secondary hormonal treatments (aminoglutethimide and ketoconazole) are less effective than initial hormonal therapy. Antineoplastic agents have little or no effectiveness in prostate cancer. Although the value of screening for and treating prostate cancer continues to be debated, many experts recommend annual screening for all men over 50. Research to identify more effective drugs for treating advanced disease continues." @default.
- W2340873090 created "2016-06-24" @default.
- W2340873090 creator A5007287270 @default.
- W2340873090 creator A5051964825 @default.
- W2340873090 date "1996-02-15" @default.
- W2340873090 modified "2023-09-26" @default.
- W2340873090 title "Prostate cancer: current and evolving strategies" @default.
- W2340873090 doi "https://doi.org/10.1093/ajhp/53.4.381" @default.
- W2340873090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8673658" @default.
- W2340873090 hasPublicationYear "1996" @default.
- W2340873090 type Work @default.
- W2340873090 sameAs 2340873090 @default.
- W2340873090 citedByCount "13" @default.
- W2340873090 crossrefType "journal-article" @default.
- W2340873090 hasAuthorship W2340873090A5007287270 @default.
- W2340873090 hasAuthorship W2340873090A5051964825 @default.
- W2340873090 hasBestOaLocation W23408730901 @default.
- W2340873090 hasConcept C121608353 @default.
- W2340873090 hasConcept C126322002 @default.
- W2340873090 hasConcept C126894567 @default.
- W2340873090 hasConcept C143998085 @default.
- W2340873090 hasConcept C2776235491 @default.
- W2340873090 hasConcept C2778311097 @default.
- W2340873090 hasConcept C2779466945 @default.
- W2340873090 hasConcept C2780101318 @default.
- W2340873090 hasConcept C2780192828 @default.
- W2340873090 hasConcept C2781406297 @default.
- W2340873090 hasConcept C29456083 @default.
- W2340873090 hasConcept C509974204 @default.
- W2340873090 hasConcept C71924100 @default.
- W2340873090 hasConceptScore W2340873090C121608353 @default.
- W2340873090 hasConceptScore W2340873090C126322002 @default.
- W2340873090 hasConceptScore W2340873090C126894567 @default.
- W2340873090 hasConceptScore W2340873090C143998085 @default.
- W2340873090 hasConceptScore W2340873090C2776235491 @default.
- W2340873090 hasConceptScore W2340873090C2778311097 @default.
- W2340873090 hasConceptScore W2340873090C2779466945 @default.
- W2340873090 hasConceptScore W2340873090C2780101318 @default.
- W2340873090 hasConceptScore W2340873090C2780192828 @default.
- W2340873090 hasConceptScore W2340873090C2781406297 @default.
- W2340873090 hasConceptScore W2340873090C29456083 @default.
- W2340873090 hasConceptScore W2340873090C509974204 @default.
- W2340873090 hasConceptScore W2340873090C71924100 @default.
- W2340873090 hasIssue "4" @default.
- W2340873090 hasLocation W23408730901 @default.
- W2340873090 hasLocation W23408730902 @default.
- W2340873090 hasOpenAccess W2340873090 @default.
- W2340873090 hasPrimaryLocation W23408730901 @default.
- W2340873090 hasRelatedWork W137193761 @default.
- W2340873090 hasRelatedWork W1980188241 @default.
- W2340873090 hasRelatedWork W1992657261 @default.
- W2340873090 hasRelatedWork W2084319043 @default.
- W2340873090 hasRelatedWork W2092129431 @default.
- W2340873090 hasRelatedWork W2092691589 @default.
- W2340873090 hasRelatedWork W2099948048 @default.
- W2340873090 hasRelatedWork W2417374591 @default.
- W2340873090 hasRelatedWork W3087899116 @default.
- W2340873090 hasRelatedWork W93186087 @default.
- W2340873090 hasVolume "53" @default.
- W2340873090 isParatext "false" @default.
- W2340873090 isRetracted "false" @default.
- W2340873090 magId "2340873090" @default.
- W2340873090 workType "article" @default.